Fusion Pharmaceuticals Inc has secured about $26 million (US$21 million) in the second close of its Series A financing. The additional funding, which brings the round to nearly $57 million (US$46 million) in total, was supplied by Adams Street Partners, Seroba Life Sciences and Varian Medical Systems Inc, among others. They join the backers of the round's first close, announced in February. Hamilton, Ontario's Fusion, a spin-out of the Centre for Probe Development and Commercialization, is developing targeted radiotherapeutics for treating cancer. It will use the additional funds raised to develop its lead program, expand its pipeline, and form new strategic partnerships.